Gilead phase 3 data shows continued viral suppression with HIV combo pill
Source: SeekingAlpha
2026-02-25 14:58:18 ET
More on Gilead Sciences
- Gilead: Downgrade To 'Hold' Rating Despite Arcellx Acquisition
- What Gilead Is Getting Through The Acquisition Of Arcellx
- Time To Take Profits On Gilead Sciences (Rating Downgrade)
- Gilead Sciences to buy Arcellx in deal worth up to $7.8B
- Gilead in up to $1.5B deal with China's Genhouse Bio for tumor candidate
Read the full article on Seeking Alpha
For further details see:
Gilead phase 3 data shows continued viral suppression with HIV combo pill
Gilead Sciences Inc.
NASDAQ: GILD
GILD Trading
0.1% G/L:
$143.95 Last:
1,456,854 Volume:
$143.56 Open:
GILD Latest News
March 03, 2026 09:00:00 am
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
March 02, 2026 08:30:00 am
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
February 25, 2026 01:44:00 pm
Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
February 24, 2026 10:58:00 am
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
GILD Stock Data
$185,419,569,657
1,228,272,827
0.07%
1237
N/A
Pharmaceuticals
Healthcare
US
Foster City
